Funding profile · Point of care allergy diagnostics

Kenota

A Kitchener, Ontario company that reported an $11 million Series A in 2020, two years after the only SEC filing on record showed a much smaller amount sold. It is listed as Inactive by Y Combinator as of September 2026.

$11MTotal raised to date, company-reported (Dec 2020, USD)
$5.3MSold of $12.1M offered, sole Form D on file (Aug 2018)
26Investors named on the Form D, about $203,700 average
$2MInitial seed, company-reported (2016, USD)

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Aug and Sep 2016 Seed, two tranches Not disclosed, reported as $2M USD Y Combinator, Tencent Holdings, Pegasus Tech Ventures, OS Fund, Fifty Years, 1517 Fund Independent
Jul 31, 2018 first sale, filed Aug 14, 2018 Equity offering, filer ExVivo Labs Inc. $12,104,996 offered; $5,296,435 sold 26 investors, not individually named Form D
Closed Aug 31, 2020 Series A $11.5M CAD ($9M USD) Led by Draper Associates; Fidelity Investments Canada ULC, Y Combinator, OS Fund, BDC Capital’s bridge financing program, BoxOne Ventures, Dr. Collin Terpstra, 1517, Fifty Years Capital BetaKit report
As of Dec 2020 Total funding to date $14M CAD ($11M USD) Includes the 2016 seed and the Series A above Company-stated

What the filings show

ExVivo Labs Inc. · Form D · filed Aug 14, 2018

First sale
Jul 31, 2018
Offered
$12,104,996 equity
Sold
$5,296,435 · $6,808,561 remaining
Investors
26 · average about $203,700
Exemption
Rule 506(b)
Related persons
Moufeed Kaddoura (executive officer, director); Eric Blondeel (executive officer, director)
Filing
SEC EDGAR, CIK 0001750062

Reading the filings

  1. The checks average about $203,700.Twenty six investors had put in $5,296,435 by the August 2018 filing, an average that fits a broad seed to growth syndicate mixing funds and individuals rather than a handful of large institutional checks.
  2. The filing predates the announced close by more than two years.The Form D’s first sale is dated July 31, 2018. BetaKit reported in December 2020 that the same round, described there as a Series A, “officially closed on August 31, 2020” at $11.5 million CAD ($9 million USD), more than double the $5,296,435 shown as sold on the sole filing. No amendment has been filed under CIK 0001750062 to update the amount, so the public record and the reported total never reconcile.
  3. The filer name lags the rebrand.The Form D was filed under ExVivo Labs Inc., the company’s original name. By the time BetaKit covered the round’s close in December 2020, the company was already using the name Kenota Health. No filing under a Kenota name appears in SEC EDGAR.
  4. Early backers reappear later.Y Combinator and 1517 Fund are named among the 2016 seed investors and again among the 2020 Series A participants, suggesting continuity from Kenota’s earliest investors through to its most recent reported round.
  5. One filing is all there is.Companies that continue an offering under Section 4(a)(2) instead of Regulation D, or that simply do not amend, file no further Form D. That gap does not prove no further money moved, but it means the $9 to $11 million total rests entirely on the company’s own account, with nothing on the public record to confirm the increase past $5.3 million.
  6. The people on the filing left.The only related persons named on the 2018 Form D are Kaddoura and Blondeel. By 2023 and 2024, Kenota’s own press releases credit a different chief technology officer, Chris Harder, and Blondeel’s own biography now lists him as having since co-founded a separate company, describing his Kenota role in the past tense.

Commercial signals

Signal Detail Source type
Regulatory FDA 510(k) K231151, Kenota 1 Total IgE, cleared May 31, 2024, filed as a Dual Track submission covering a CLIA waiver. Public record
Clinical evidence on file No clinical diagnostic sensitivity or specificity study performed. Performance based on bench testing and reference intervals from 117 healthy donors. Public record
Method comparison study Company-described 360-patient study at three US allergy clinics, early 2023, fingerstick versus venous blood. No peer-reviewed publication found. Company-stated
Health Canada licence No public medical device licence for the Kenota 1 system was located in the searches run for this profile. Not found
Company website Live and describing the FDA clearance as of a May 18, 2025 archived capture. As of September 2026 the domain kenota.com resolves to an unrelated site. Wayback capture
Operating status Y Combinator lists the company Inactive. A University of Waterloo Velocity incubator page, undated, still lists it Active. Conflicting status

What to watch

  • An amended Form D that would reconcile the $5.3 million sold on file with the $9 to $11 million the company has reported raising.
  • A Health Canada medical device licence for the Kenota 1 system, which has not been found.
  • Whether kenota.com is restored, or whether any successor or acquirer is named.
  • Named specific IgE allergen panel submissions, which the company said in 2024 it was developing for FDA review.

The Kenota story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Isabl: Shared investor: Boxone Ventures. A Memorial Sloan Kettering spin out that reads the whole tumor genome and transcriptome instead of a gene panel
  • Verge Genomics: Shared investor: Os Fund. The first company to carry a drug from an AI platform into ALS patients
  • Sequence Bio: Shared investor: Bdc Capital. A St
  • Lygos: Shared investor: Os Fund. A Berkeley Lab spinout that taught yeast to make malonic acid without cyanide, then became a specialty chemicals supplier whose polymers end up in shampoo, diapers and

Sources

  1. Public recordForm D, ExVivo Labs Inc.SEC EDGAR · filed Aug 14, 2018
  2. Public recordSEC EDGAR company search results for ExVivo Labs Inc., CIK 0001750062SEC EDGAR · accessed Sep 2026
  3. Public recordFDA 510(k) summary, K231151, Kenota 1 Total IgEFDA · decision May 31, 2024
  4. IndependentKenota 1 Total IgE; Kenota 1 (instrument), 510(k) device recordFDA Browser, Innolitics · accessed Nov 2024
  5. IndependentToday in Funding: Potloc, Aifred Health, Kenota Health, IndiegrafBetaKit, Scott McLean · Dec 10, 2020
  6. IndependentDespite small decline in deals, Waterloo Region remained a healthy startup ecosystem in 2020BetaKit, Jessica Galang · Apr 22, 2021
  7. IndependentExVivo Labs company entryGolden, wayback capture · Dec 1, 2018
  8. CompanyKenota (formerly ExVivo Labs) company pageY Combinator · accessed Sep 25, 2026
  9. CompanyKenota Health Announces FDA Submission for Allergy Testing SystemEIN Presswire · Jul 20, 2023
  10. CompanyKenota Health System Receives FDA Clearance and CLIA Waiver Marketing Approval for IgE TestingEIN Presswire · Jun 3, 2024
  11. CompanyKenota Health homepage, archived captureInternet Archive Wayback Machine · captured Feb 26, 2024 and May 18, 2025
  12. CompanyKenota Health portfolio entryUniversity of Waterloo Velocity · accessed Sep 25, 2026

Compiled from SEC and other public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Kenota. This page is not an offer to sell or a recommendation to buy any security.